Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events
P. Budde, J.L. Marte, H.-D. Zucht, S. Bhandari, M. Tuschen, P. Schulz-Knappe, R.A. Madan, J.L. Gulley, J. Schlom
Extract from: Annals of the Rheumatic Diseases 2018; 77(Suppl 2):247–247.
Conclusions:
AABs that target antigens involved in cancer signalling pathways are associated with irAEs following prostvac plus checkpoint inhibitor combination therapy. In contrast, AABs targeting immune response pathways were found in patients who do not develop iRAEs and may counteract the action of inflammatory molecules. Similarly, anti-cytokine AABs have been found in autoimmune diseases, were they appear to counteract the pathological effects of cytokines. Further studies in larger sample sets are needed to confirm these findings.